The formation of [3H]inositol phosphates in human platelets by palmitoyl lysophosphatidic acid is blocked by indomethacin.
The intracellular Ca2+ thresholds for platelet shape change and aggregation by A23187 and palmitoyl lysophosphatidic acid were approximately 350 and 750 nM, respectively, as estimated using quin2. The similar thresholds for these two agonists imply they activate platelets through a similar mechanism. In the absence of cyclooxygenase inhibitors, both agents induce the formation of [3H]inositol phosphates, reflecting the activation of phospholipase C. This activation of phospholipase C is blocked by the cyclooxygenase inhibitor indomethacin. It is suggested that platelet activation by palmitoyl lysophosphatidic acid involves an initial mobilization of intracellular Ca2+ with subsequent activation of phospholipase A2; the arachidonic acid metabolites formed then stimulate phospholipase C.
D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D000001:Calcimycin / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors; D004075:Diglycerides / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D007295:Inositol Phosphates / Q000096:biosynthesis*; D008246:Lysophospholipids; D010712:Phosphatidic Acids / Q000494:pharmacology*; D010766:Phosphorylation; D010974:Platelet Aggregation / Q000187:drug effects; D013403:Sugar Phosphates / Q000096:biosynthesis*; D010738:Type C Phospholipases / Q000378:metabolism
D016861:Cyclooxygenase Inhibitors; D004075:Diglycerides; D007295:Inositol Phosphates; D008246:Lysophospholipids; D010712:Phosphatidic Acids; D013403:Sugar Phosphates; C044297:1,2-didecanoylglycerol; C026671:1-palmitoyl-lysophosphatidic acid; D000001:Calcimycin; D010738:Type C Phospholipases; D002118:Calcium; D007213:Indomethacin